{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:41:45Z","timestamp":1766050905501,"version":"build-2065373602"},"reference-count":27,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2025,10,3]]},"DOI":"10.1080\/13543776.2025.2548586","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T06:34:29Z","timestamp":1755758069000},"page":"1063-1072","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Implementation and outcomes of China\u2019s drug patent linkage system: lessons from international experience"],"prefix":"10.1080","volume":"35","author":[{"given":"Yu","family":"Chen","sequence":"first","affiliation":[{"name":"National Medical Products Administration","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjuan","family":"Liu","sequence":"additional","affiliation":[{"name":"National Medical Products Administration","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suju","family":"Li","sequence":"additional","affiliation":[{"name":"National Medical Products Administration","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Xu","sequence":"additional","affiliation":[{"name":"National Medical Products Administration","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-024-01035-x"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-83114-1_12"},{"key":"e_1_3_4_5_1","unstructured":"U.S. Food and Drug Administration. Orange Book Preface[Internet]. [cited 2025 Jan 15]. Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/orange-book-preface"},{"key":"e_1_3_4_6_1","unstructured":"U.S. Food and Drug Administration. Orange Book: approved drug products with therapeutic equivalence evaluations [internet]. [cited 2025 Jan 30]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/"},{"key":"e_1_3_4_7_1","unstructured":"Health Canada. Guidance document: patented medicines (notice of compliance) regulations [Internet]. [cited 2025 Feb 1]. Available from: https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drug-health-product-review-approval\/drug-products\/guidance-documents\/pm-noc-regulations-guid-ld-eng.pdf"},{"key":"e_1_3_4_8_1","unstructured":"Health Canada. Patent register [Internet]. [cited 2025 Feb 1]. Available from: https:\/\/pr-rdb.hc-sc.gc.ca\/pr-rdb\/index-eng.jsp"},{"key":"e_1_3_4_9_1","unstructured":"Cheng YS Wu LJ. Review of the patent link system for pharmaceuticals in South Korea [Internet]. 2020 [cited 2025 Feb 1]. Available from: https:\/\/baijiahao.baidu.com\/s?id=1676171942590771954&wfr=spider&for=pc"},{"key":"e_1_3_4_10_1","unstructured":"U.S. Food and Drug Administration. Orange Book questions and answers guidance for industry [Internet]. 2022 [cited 2025 Feb 15]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/orange-book-questions-and-answers-guidance-industry"},{"key":"e_1_3_4_11_1","unstructured":"National Institute of Food and Drug Safety Evaluation. Guide to drug approval system in Korea [Internet]. 2017 [cited 2025 Feb 2]. Available from: https:\/\/www.mfds.go.kr\/eng\/brd\/m_60\/view.do?seq=71608"},{"key":"e_1_3_4_12_1","unstructured":"Singapore Ministry of Health. Health products (therapeutic products) regulations 2016[Internet]. 2016 [cited 2025 Feb 5]. https:\/\/sso.agc.gov.sg\/SL\/HPA2007-S329-2016?DocDate=20241025&WholeDoc=1"},{"key":"e_1_3_4_13_1","unstructured":"National Medical Products Administration (NMPA). Implementation measures for the early resolution mechanism of pharmaceutical patent disputes[internet]. 2021 [cited 2025 Feb 12]. Available from: http:\/\/www.nmpa.gov.cn\/"},{"key":"e_1_3_4_14_1","unstructured":"Qing JJ. Intellectual property practice sharing: the battle between generic drugs and original drugs-exploring the legal and practical aspects of Singapore\u2019s patent link system[Internet]. 2021 [cited 2025 Feb 4]. Available from: https:\/\/zhuanlan.zhihu.com\/p\/381270335"},{"key":"e_1_3_4_15_1","unstructured":"U.S. Food and Drug Administration. Small business assistance | 180-day generic drug exclusivity [internet]. 2023 [cited 2025 Feb 15]. Available from: https:\/\/www.fda.gov\/drugs\/cder-small-business-industry-assistance-sbia\/small-business-assistance-180-day-generic-drug-exclusivity"},{"key":"e_1_3_4_16_1","unstructured":"Government of Canada. Patented medicines (notice of compliance) regulations (SOR\/93\u2013133) [Internet]. [cited 2025 Feb 16]. Available from: https:\/\/laws-lois.justice.gc.ca\/eng\/regulations\/SOR-93-133\/page-2.html#docCont"},{"key":"e_1_3_4_17_1","unstructured":"General Office of the State Council. China. Opinions on deepening the reform of evaluation and approval system and encouraging innovation in drugs and medical devices [internet]. 2017 [cited 2025 Feb 8]. Available from: http:\/\/www.gov.cn\/zhengce\/content\/2017-10\/08\/content_5230105.htm"},{"issue":"24","key":"e_1_3_4_18_1","first-page":"3693","article-title":"Analysis of pharmaceutical patent linkage system in the United States and Canada","volume":"39","author":"Zhang F","year":"2023","unstructured":"Zhang F, Wen BS. Analysis of pharmaceutical patent linkage system in the United States and Canada. Chin J Clin Pharmacol. 2023;39(24):3693\u20133696.","journal-title":"Chin J Clin Pharmacol"},{"key":"e_1_3_4_19_1","unstructured":"Chen JY. Interpretation of the Canadian medical intellectual property rights protection system. Intellect Property Front. 2020. Available from: https:\/\/www.sohu.com\/a\/415762823_120133310"},{"key":"e_1_3_4_20_1","unstructured":"U.S. Food and Drug Administration. Patents and exclusivities for generic drug products [internet]. 2024 [cited 2025 Feb 16]. Available from: https:\/\/www.fda.gov\/drugs\/cder-conversations\/patents-and-exclusivities-generic-drug-products"},{"issue":"3","key":"e_1_3_4_21_1","article-title":"The South Korean patent linkage system: a model for reforming the United States Hatch-Waxman Act","volume":"33","author":"Kimberlee TR","year":"2019","unstructured":"Kimberlee TR. The South Korean patent linkage system: a model for reforming the United States Hatch-Waxman Act. Emory Int Law Rev. 2019;33(3).","journal-title":"Emory Int Law Rev"},{"key":"e_1_3_4_22_1","unstructured":"Tong HY. Strategies for generic drug patent challenges under the patent linkage system. China Pharm News; 2022. Available from: https:\/\/bk.cnpharm.com\/zgyyb\/2022\/05\/13\/322168.html"},{"key":"e_1_3_4_23_1","unstructured":"Anti-Monopoly and Anti-Unfair Competition Committee of the State Council. Guidelines on anti-monopoly in the pharmaceutical sector [internet]. [cited 2025 Feb 22]. Available from: https:\/\/www.samr.gov.cn\/zw\/zfxxgk\/fdzdgknr\/fldzfys\/art\/2025\/art_4f615267290d443f9b4e571774ed3d2a.html"},{"key":"e_1_3_4_24_1","unstructured":"Supreme People\u2019s Court of the People\u2019s Republic of China. Provisions on several issues concerning the application of law in the trial of pharmaceutical patent linkage dispute cases. Gazette of the Supreme People\u2019s Court of the People\u2019s Republic of China [Internet]. 2021 [cited 2025 Feb 25]. Available from: http:\/\/gongbao.court.gov.cn\/Details\/f918b5b65e896178fe577e2da09d5b.html"},{"key":"e_1_3_4_25_1","unstructured":"Li ZL Zhang XY. Series on pharmaceutical patent protection 13: analysis of key issues judicial rules and solutions in the patent linkage system (part 3) [Internet]. Sohu News; 2024 [cited 2025 Jul 3]. Available from: https:\/\/news.sohu.com\/a\/825951157_121123699"},{"key":"e_1_3_4_26_1","unstructured":"Law Firm H. Case adjudication rules of China\u2019s drug patent linkage system (part 2)[Internet]. Haiwen\u00b7insights. 2024 [cited 2025 Jul 3]. Available from: https:\/\/mp.weixin.qq.com\/s?__biz=MzA5MjYzNDQyMw==&mid=2658246401&idx=1&sn=aa3881c82c226dfbe3ff0fa3345c0dea&chksm=8bef1359bc989a4f0382a471d7893af38c25fab04e705fa8ba3e7863c72d017295b5d8cd1059&scene=27"},{"key":"e_1_3_4_27_1","unstructured":"Cheng L. Is posting online considered infringement? The patent battle between originator drugs and generic drugs. R&D; 2024 [cited 2025 Jul 3]. Available from: https:\/\/mp.weixin.qq.com\/s?__biz=MzI4MTU2OTEyNQ==&mid=2247571171&idx=1&sn=69f00fa50c7e9efb551169b1a90b5865&chksm=ea90246ccc5bc9fd77548a34f750212711fb9e4b102cbe264c35215dedeee1441be06ab6b0c0&scene=27"},{"key":"e_1_3_4_28_1","unstructured":"WIPO. Global innovation index 2024 [Internet]. 2024 [cited 2025 Jul 5]. Available from: https:\/\/www.wipo.int\/web-publications\/global-innovation-index-2024\/en\/"},{"key":"e_1_3_4_29_1","unstructured":"Miao Q. A patent case has led to nearly 9 billion in investment and foreign companies have \u201cvoted\u201d in support of China\u2019s intellectual property protection. First Financial News [Internet]; 2024 [cited 2025 Jul 6]. Available from: https:\/\/www.163.com\/dy\/article\/J5F0N5GQ051994QM.html"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2025.2548586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:29:59Z","timestamp":1759480199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2025.2548586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,3]]}},"alternative-id":["10.1080\/13543776.2025.2548586"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2025.2548586","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"type":"print","value":"1354-3776"},{"type":"electronic","value":"1744-7674"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}